Pharming Group NV - Adr (PHAR) Institutional Buying & Selling Tracker (Q2 2026)

PHAR ranks #8651 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

PHAR is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

18 institutions disclose a position in PHAR, but none treat it as a major bet — even MAC Alpha Capital Management, LP, its most concentrated holder, allocates just 1.4% of its own portfolio to it.

Silverberg Bernstein Capital Management LLC has trimmed its PHAR position for two straight quarters, cutting it by $316.1K while still holding $577.1K.

PHAR is down 2% today, but institutions show net buying of $2.9M this quarter — a divergence between today's price move and the underlying institutional flow.

PHAR closed its latest fiscal year with net income of $2.5M.

• Profitable — net income of $2.5M in the latest fiscal year
• Revenue grew 26.6% year over year
• Net income improved year over year, from -$11.8M to $2.5M
• Generated $54.7M in positive operating cash flow
• Current ratio of 2.59x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.05x equity — within a conventional range